Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review
Authors:
Open Access
- 1 June 2021
- journal article
- review article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 13 (6) , 3692-3707
Abstract
Background: Small-cell lung cancer (SCLC) accounts for 12–15% of lung cancers and is associated with poor survival outcomes and high symptom burden. This study employed a broad, systematic search strategy and timeframe to identify evidence on real-world treatment patterns and outcomes for SCLC outside the USA, including understanding sub-populations such as extensive-stage (ES) or limited-stage (LS) disease. Methods: Databases (MEDLINE, Embase, and EBM reviews) were searched for journal articles published in the English language between 1 January 2000–1 March 2020 and supplemented by hand searching of conference abstracts and posters presented at conferences between 1 January 2016–1 March 2020 reporting real-world treatment outcomes in patients with SCLC. A targeted clinical guideline review was also completed. Results: One-hundred studies provided quantitative data; 57 were available as full-text articles, whilst the remaining 43 were presented as abstracts or posters. The majority (80 studies, 80%) of included studies reported treatment in the first-line setting, where platinum-based chemotherapy and chemoradiotherapy was the most commonly used treatment strategy, in line with current treatment guidelines in SCLC. First-line treatments were found to have a high response rate; however, most patients relapsed early. No studies reported treatment or outcomes with immune-oncology therapies. Second-line treatment options were very limited, and primarily consisted of either re-treatment with first-line regimen or topotecan, but the prognosis for these patients remained poor. Outcomes were particularly poor amongst those with ES or relapsed disease vs. LS disease. Conclusions: SCLC treatment patterns and short survival outcomes have remained constant over the previous 20 years. Due to the search timeframe, none of the studies identified reported on the impact of recently approved immune-oncology therapies in SCLC. Further data is needed on the impact of immunotherapies on treatment patterns and real-world outcomes in SCLC.Keywords
This publication has 55 references indexed in Scilit:
- Surgical treatment of early stage small cell lung cancerAsian Cardiovascular and Thoracic Annals, 2012
- Uptake and Tolerance of Chemotherapy in Elderly Patients with Small Cell Lung Cancer and Impact on SurvivalJournal of Cancer Epidemiology, 2012
- Patterns of recurrence and outcome in patients with surgically resected small cell lung cancerInternational Journal of Clinical Oncology, 2011
- Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasisCancer, 2011
- Characteristics, treatment patterns and outcomes of patients with small cell lung cancer—A retrospective single institution analysisLung Cancer, 2011
- Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancerCancer, 2010
- Guidelines on the radical management of patients with lung cancerThorax, 2010
- Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology LjubljanaRadiology and Oncology, 2010
- The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patientsLung Cancer, 2008
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006